Despite its experimental Alzheimer’s drug failing an initial study, Roche Holding may re-run its trial given the success of a similar treatment from Biogen.
Roche says it may re-run its gantenerumab trial -- halted in December because patients weren’t benefiting -- with a higher dose and other adjustments.
Like Biogen’s drug aducanumab, Roche's gantenerumab is an antibody that targets the beta amyloid protein, which suggests that if Biogen’s drug works, Roche's drug should also work. Biogen's aducanumab was found to lower plaque in the brain and reduced cognitive decline by as much as 71 percent.
Read the Bloomberg article
